An investment of up to $550 million by 2030 will establish the Indianapolis site as a hub for manufacturing of Roche’s continuous glucose monitoring solution.
Roche, announced it plans to invest up to $550 million in its Diagnostics site in Indianapolis by 2030. The site will become a major hub for the manufacturing of Roche’s continuous glucose monitoring systems – marking a new milestone in Roche’s long history of revolutionizing healthcare across the globe.
Health Technology Insights: QuantHealth Launches First Pharmaco-Clinical AI Model for Life Sciences
Indianapolis serves as the North American headquarters for Roche Diagnostics, part of the Roche Group – the world’s largest biotech company. This latest expansion underscores Roche’s commitment to advancing science, driving innovation, and delivering cutting-edge solutions that improve patient outcomes.
With more than 38 million Americans living with diabetes,¹ access to effective disease management solutions is crucial. To address this growing need, Roche is investing in a new CGM manufacturing facility in Indianapolis. CGM technologies offer essential support for daily diabetes management, and this investment will help advance Roche’s mission to improve patient care through innovation.
“The challenges of diabetes are pervasive, with millions of Americans living with the constant vigilance and countless daily decisions the disease requires,” said Brad Moore, President and CEO of Roche Diagnostics North America. “By expanding our manufacturing capabilities in Indianapolis, we ensure reliable access to innovative monitoring solutions for individuals living with diabetes in the U.S. and worldwide.”
Health Technology Insights: BlossomHill Therapeutics Appoints Jason Keyes as CFO and EVP
The Indianapolis campus houses key operations, including U.S. research and development, laboratories, manufacturing, distribution, IT and administrative functions. It currently produces approximately 5.2 billion Accu-Chek diabetes test strips annually and serves as one of two global distribution hubs focused on serving the U.S. market and supporting distribution to 53 countries worldwide.
Building on more than $800 million in U.S. investments made at Roche U.S. sites since 2015, this new commitment reinforces Roche’s longterm dedication to U.S. operations and highlights the country’s central role in the company’s global strategy.
The expansion is expected to generate hundreds of highly-skilled manufacturing jobs and thousands of construction jobs, providing a significant boost to Indiana’s economy. It will also enhance domestic production capabilities and reduce dependency on imports – aligning with national efforts to strengthen local manufacturing.
Health Technology Insights: Nelipak Healthcare Packaging to Expand Operations in Costa Rica
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
